Company news
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news
Apellis Pharmaceuticals, Inc. news releases on 6ix. Latest, Dec 16, 2022: Apellis Submits Marketing Authorization Application to the European Medicines Agency…
Press releases — page 3
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
December 15, 2022
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
November 17, 2022
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 6, 2022
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
November 2, 2022
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
November 2, 2022
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
October 30, 2022
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
September 29, 2022
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
September 29, 2022
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
September 11, 2022
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
August 23, 2022
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 7, 2022
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
July 31, 2022
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 26, 2022
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
July 18, 2022
Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
July 13, 2022
Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
June 21, 2022
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
June 9, 2022
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
June 6, 2022
Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
May 31, 2022
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 11, 2022
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
May 4, 2022
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
May 2, 2022
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
May 1, 2022
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
April 25, 2022
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
April 20, 2022
Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 3, 2022
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
March 27, 2022
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
March 23, 2022
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 22, 2022
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
March 15, 2022
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 27, 2022
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
February 21, 2022
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
December 14, 2021
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
December 14, 2021
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
December 12, 2021
Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 28, 2021
Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
November 11, 2021
Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
November 9, 2021
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 7, 2021
Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
November 3, 2021
Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
October 31, 2021
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
October 14, 2021
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
October 14, 2021
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
September 29, 2021
Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 19, 2021
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
September 8, 2021
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer
September 2, 2021
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 8, 2021